These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 23301371)
1. Status and costs of smoking cessation in countries of the Eastern Mediterranean Region. Heydari G; Talischi F; Mojgani N; Masjedi MR; Algouhmani H; Lando HA; Ahmady EA East Mediterr Health J; 2012 Nov; 18(11):1102-6. PubMed ID: 23301371 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. Lutz MA; Lovato P; Cuesta G Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880 [TBL] [Abstract][Full Text] [Related]
3. Availability, Sales, and Affordability of Tobacco Cessation Medicines in Kerala, India. Sarma S; Harikrishnan S; Baldridge AS; Devarajan R; Mehta A; Selvaraj S; Ali MK; Mohanan PP; Prabhakaran D; Huffman MD Circ Cardiovasc Qual Outcomes; 2017 Nov; 10(11):. PubMed ID: 29150536 [TBL] [Abstract][Full Text] [Related]
4. Smoking cessation services in the Eastern Mediterranean Region: highlights and findings from the WHO Report on the Global Tobacco Epidemic 2019. AlMulla A; Hassan-Yassoub N; Fu D; El-Awa F; Alebshehy R; Ismail M; Fraser CP East Mediterr Health J; 2020 Jan; 26(1):110-115. PubMed ID: 32043553 [TBL] [Abstract][Full Text] [Related]
5. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua. Lutz MA; Lovato P; Cuesta G Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece. Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870 [TBL] [Abstract][Full Text] [Related]
7. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain. Rejas-Gutiérrez J; Bruguera E; Cedillo S Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Hoogendoorn M; Welsing P; Rutten-van Mölken MP Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492 [TBL] [Abstract][Full Text] [Related]
9. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Bertram MY; Lim SS; Wallace AL; Vos T Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support. Higashi H; Barendregt JJ Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602 [TBL] [Abstract][Full Text] [Related]
11. Reprint of: Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. Kalkhoran S; Benowitz NL; Rigotti NA J Am Coll Cardiol; 2018 Dec; 72(23 Pt B):2964-2979. PubMed ID: 30522631 [TBL] [Abstract][Full Text] [Related]
12. Smoking Cessation Support Services at Community Pharmacies in the UK: A Systematic Review. Peletidi A; Nabhani-Gebara S; Kayyali R Hellenic J Cardiol; 2016; 57(1):7-15. PubMed ID: 26856195 [No Abstract] [Full Text] [Related]
13. Cost-utility analysis of smoking cessation to prevent operative complications following elective abdominal colon surgery. Kulaylat AS; Hollenbeak CS; Soybel DI Am J Surg; 2018 Dec; 216(6):1082-1089. PubMed ID: 30262122 [TBL] [Abstract][Full Text] [Related]
14. Economic Impact of Financial Incentives and Mailing Nicotine Patches to Help Medicaid Smokers Quit Smoking: A Cost-Benefit Analysis. Sung HY; Penko J; Cummins SE; Max W; Zhu SH; Bibbins-Domingo K; Kohatsu ND Am J Prev Med; 2018 Dec; 55(6 Suppl 2):S148-S158. PubMed ID: 30454669 [TBL] [Abstract][Full Text] [Related]
15. Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany. Aumann I; Treskova M; Hagemann N; von der Schulenburg JM Appl Health Econ Health Policy; 2016 Aug; 14(4):441-452. PubMed ID: 27021824 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand. Tosanguan J; Chaiyakunapruk N Addiction; 2016 Feb; 111(2):340-50. PubMed ID: 26360507 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of varenicline for smoking cessation. Keiding H Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744 [TBL] [Abstract][Full Text] [Related]
19. [Smoking cessation: Pharmacological strategies different from standard treatments]. Underner M; Perriot J; Peiffer G; Harika-Germaneau G; Jaafari N Rev Pneumol Clin; 2018 Sep; 74(4):205-214. PubMed ID: 29773262 [TBL] [Abstract][Full Text] [Related]
20. National trends in the provision of smoking cessation aids within the Veterans Health Administration. Jonk YC; Sherman SE; Fu SS; Hamlett-Berry KW; Geraci MC; Joseph AM Am J Manag Care; 2005 Feb; 11(2):77-85. PubMed ID: 15726855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]